Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

Item

http://www.wikidata.org/entity/Q35818165

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@ast

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@en

type

Item

label

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@ast

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@en

prefLabel

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@ast

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@en

P1476

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

@en

P2093

Daniel Pelletier

http://www.w3.org/2001/XMLSchema#string

Donald E Goodkin

http://www.w3.org/2001/XMLSchema#string

Jerome Stone

http://www.w3.org/2001/XMLSchema#string

Mariko Kita

http://www.w3.org/2001/XMLSchema#string

Robert J Fox

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

P304

S58-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1191/1352458504MS1032OA

http://www.w3.org/2001/XMLSchema#string

P478

10 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Olaf Stüve

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8489127

http://www.w3.org/2001/XMLSchema#string

P698

15218811

http://www.w3.org/2001/XMLSchema#string

P921

primary progressive multiple sclerosis